In terms of relative impact compared to lifelong vaccine immunity, our 5-year vaccine duration looks like 20-year vaccine duration in the IC/Harvard and Sacema models. We think that two phenomena may contribute to the difference in model results with waning:
a difference in the proportion of incident 9v-type HPV cases occurring in the middle ages (~20-44) and affected by a waning versus lifelong vaccine
in our compartmental model, vaccine coverage "leaks" into older ages and is less potent in the middle ages in the mid-term. This effect dampens some of the waning vaccine effect seen in the Sacema model
In terms of relative impact compared to lifelong vaccine immunity, our 5-year vaccine duration looks like 20-year vaccine duration in the IC/Harvard and Sacema models. We think that two phenomena may contribute to the difference in model results with waning: